News
Pfizer Inc faces a new challenge as Enanta Pharmaceuticals sues over a patent infringement concerning Paxlovid in the EU.
COVID cases go up nationwide every summer, but PSAs cautioning the public about that fact seem to be an endangered species.
Enata Pharmaceuticals is suing Pfizer in a European Union court, alleging Pfizer's Paxlovid Covid-19 antiviral violates one of its patents. Enata said its patent, published Wednesday in the European ...
Pfizer (PFE) stock in focus as Enanta Pharmaceuticals (ENTA) sues the pharma giant in the EU, claiming its COVID pill ...
Enata Pharmaceuticals is suing Pfizer in a European Union court, alleging Pfizer's Paxlovid Covid-19 antiviral violates one of its patents. Enata said its patent, published Wednesday in the European ...
Released Tuesday, the AAP's recommendations call for routine vaccination of children ages 6 months to 2 years, citing ...
5d
TipRanks on MSNTraws Pharma Gains Approval for Phase 2 COVID-19 Trials
Traws Pharma ( ($TRAW) ) has shared an update. On August 18, 2025, Traws Pharma announced approval from the Human Research Ethics Committee to ...
Pfizer Inc. just got a price target bump from Citi. Following a robust Q2, Citi upgraded Pfizer's price target from $25 to ...
Following the company’s strong Q2 performance, Citi raised its price target on Pfizer Inc. (NYSE:PFE) from $25 to $26 on ...
Traws Pharma, Inc. ( NASDAQ: TRAW) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Charles Parker - Interim Chief Financial Officer David Pauza - Corporate Participant Iain D. Dukes - ...
Pfizer (PFE 0.06%) has been a terrible investment over the past three years. Revenue and earnings have generally moved in the wrong direction, as the company has been unable to fo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results